Financial Counselors Inc. Buys 577 Shares of West Pharmaceutical Services, Inc. (WST)

Financial Counselors Inc. lifted its stake in West Pharmaceutical Services, Inc. (NYSE:WST) by 4.0% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 14,994 shares of the medical instruments supplier’s stock after buying an additional 577 shares during the period. Financial Counselors Inc.’s holdings in West Pharmaceutical Services were worth $1,417,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of WST. BlackRock Inc. boosted its stake in shares of West Pharmaceutical Services by 8,884.7% in the first quarter. BlackRock Inc. now owns 5,805,036 shares of the medical instruments supplier’s stock valued at $473,749,000 after buying an additional 5,740,426 shares during the period. Riverbridge Partners LLC bought a new stake in shares of West Pharmaceutical Services in the second quarter valued at approximately $48,340,000. Vanguard Group Inc. boosted its stake in shares of West Pharmaceutical Services by 6.5% in the first quarter. Vanguard Group Inc. now owns 6,440,844 shares of the medical instruments supplier’s stock valued at $525,637,000 after buying an additional 392,516 shares during the period. Prudential Financial Inc. boosted its stake in shares of West Pharmaceutical Services by 149.6% in the second quarter. Prudential Financial Inc. now owns 400,270 shares of the medical instruments supplier’s stock valued at $37,834,000 after buying an additional 239,906 shares during the period. Finally, AMI Asset Management Corp boosted its stake in shares of West Pharmaceutical Services by 963.0% in the second quarter. AMI Asset Management Corp now owns 248,534 shares of the medical instruments supplier’s stock valued at $23,491,000 after buying an additional 225,154 shares during the period. Institutional investors and hedge funds own 91.25% of the company’s stock.

Shares of West Pharmaceutical Services, Inc. (NYSE WST) opened at 91.34 on Tuesday. The firm’s 50-day moving average price is $87.40 and its 200 day moving average price is $89.11. The company has a market capitalization of $6.76 billion, a PE ratio of 39.20 and a beta of 1.13. West Pharmaceutical Services, Inc. has a 1-year low of $70.17 and a 1-year high of $99.91.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. West Pharmaceutical Services had a net margin of 11.42% and a return on equity of 14.02%. The firm had revenue of $397.60 million during the quarter, compared to the consensus estimate of $406 million. During the same period last year, the firm earned $0.59 EPS. The business’s quarterly revenue was up 2.5% compared to the same quarter last year. Equities analysts predict that West Pharmaceutical Services, Inc. will post $2.68 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 1st. Shareholders of record on Wednesday, October 18th will be issued a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.61%. This is an increase from West Pharmaceutical Services’s previous quarterly dividend of $0.13. The ex-dividend date is Tuesday, October 17th. West Pharmaceutical Services’s dividend payout ratio (DPR) is presently 22.22%.

Several equities research analysts recently issued reports on the company. Zacks Investment Research upgraded West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a research note on Friday, June 23rd. BidaskClub cut West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, Jefferies Group LLC restated a “hold” rating and set a $90.00 target price on shares of West Pharmaceutical Services in a research note on Thursday, June 8th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $90.18.

WARNING: “Financial Counselors Inc. Buys 577 Shares of West Pharmaceutical Services, Inc. (WST)” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.themarketsdaily.com/2017/09/12/financial-counselors-inc-buys-577-shares-of-west-pharmaceutical-services-inc-wst.html.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply